360
Participants
Start Date
October 4, 2016
Primary Completion Date
April 12, 2017
Study Completion Date
June 20, 2017
ACT-541468 5 mg
Capsule for oral administration containing ACT-541468 at a strength of 5 mg
ACT-541468 10 mg
Capsule for oral administration containing ACT-541468 at a strength of 10 mg
ACT-541468 25 mg
Capsule for oral administration containing ACT-541468 at a strength of 25 mg
Zolpidem
Over-encapsulated zolpidem tablet at a strength of 10 mg
Placebo 1
Placebo capsules matching ACT-541468 capsules
Placebo 2
Placebo capsules matching over-encapsulated zolpidem
Investigator Site, Budapest
Investigator Site, Törökbálint
Investigator Site, Szeged
Investigator Site, New York
Investigator Site, Berlin
Investigator Site, Berlin
Investigator Site, Berlin
Investigator Site, Schwerin
Investigator Site, Schwerin
Investigator Site, Hamburg
Investigator Site, Hamburg
Investigator Site, Madrid
Investigator Site, Hanover
Investigator Site, Atlanta
Investigator Site, Haifa
Investigator Site, DeLand
Investigator Site, Hollywood
Investigator Site, Coral Gables
Investigator Site, Miami
Investigator Site, Brandon
Investigator Site, Clearwater
Investigator Site, Cincinnati
Investigator Site, Indianapolis
Investigator Site, Novi
Investigator Site, Zaragoza
Investigator Site, Chicago
Investigator Site, Beersheba
Investigator Site, Las Vegas
Investigator Site, Santa Monica
Investigator Site, Upland
Investigator Site, Dresden
Investigator Site, Barcelona
Investigator Site, Barcelona
Investigator Site, Gothenburg
Investigator Site, Örebro
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
INDUSTRY